Eloxx Pharmaceuticals, Inc. — Q2 2021 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2021. Eloxx is a clinical-stage biopharmaceutical company developing ribosome-modulating therapies for rare diseases. It has no approved products and reported no product revenue.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $5.7m | $3.7m | $9.8m | $8.5m |
| General and administrative expense | $7.4m | $3.8m | $11.7m | $8.9m |
| Acquired in-process R&D expense | $22.7m | — | $22.7m | — |
| Net loss | $36.1m | $7.9m | $44.8m | $21.8m |
| Basic and diluted loss per share | $0.54 | $0.20 | $0.84 | $0.54 |
Operating margins are not meaningful because the company has not generated revenue. Q2 operating expenses rose 371% year over year; the increase principally reflects the $22.7m Zikani acquired IPR&D charge, higher R&D activity, and higher G&A, including stock compensation and merger-related costs. Six-month operating expenses increased 107%; the prior-year period included $4.0m of restructuring charges, versus none in 2021.
- Cash and liquidity: Cash and cash equivalents were $56.7m at June 30, 2021, versus $24.7m at December 31, 2020; restricted cash was $0.2m. Current assets were $58.6m and current liabilities $15.2m, implying working capital of approximately $43.3m.
- Cash flow: Six-month operating cash use was $17.5m, compared with $18.2m a year earlier. Investing activities provided $2.1m, mainly cash acquired with Zikani. Financing activities provided $47.6m, primarily net public-offering proceeds of $47.7m. Cash, cash equivalents and restricted cash increased $32.3m to $57.0m.
- Debt: Balance-sheet current and long-term debt totaled $9.3m. The debt note reports $8.7m of scheduled principal payments, less $0.3m unamortized discount, and a $0.9m final fee; the term loan matures in January 2023. Its stated interest rate was 5.75% at June 30, 2021. A separate $0.8m PPP loan bears 1% interest, with payments scheduled to begin September 2021; forgiveness remained subject to lender/SBA approval.
Material changes and business developments
- On April 1, 2021, Eloxx acquired preclinical-stage Zikani in an asset acquisition, issuing 7.6m common shares. The preliminary purchase-price allocation included $22.2m for acquired IPR&D, expensed because it had no alternative future use; the recorded expense was $22.7m, including transaction costs allocated to the charge. The valuation and allocation were preliminary.
- On May 13, Eloxx completed an underwritten offering of 38.3m shares at $1.35 per share, generating approximately $47.7m net proceeds. Common shares outstanding were 86.2m at June 30 and 86.2m on August 9, 2021.
- The six-month loss more than doubled year over year, reflecting the acquisition charge and higher operating costs; the comparison also includes prior-year restructuring expense. R&D and G&A expense classifications for 2020 were reclassified, with no effect on total expenses, net loss or cash flow.
Outlook, commentary and risks
- Management said June 30 cash was expected to fund current and planned operations for at least 12 months from issuance of the financial statements. The company expects continuing losses and cash use, and may need additional financing; no financing is committed. Failure to raise capital could lead to reduced spending, workforce reductions or curtailed development.
- ELX-02 was in Phase 2 development for cystic fibrosis in patients with nonsense mutations. The company said it believed it had enrolled enough patients to assess biological activity and expected to present data from the first four treatment arms in Q4 2021. Trials had been temporarily paused during COVID-19 and later resumed; further disruption and enrollment or completion delays remained possible.
- The company planned to file an IND in 2022 for a potential oral therapy targeting recessive dystrophic and junctional epidermolysis bullosa. Zikani’s TURBO-ZM platform was at the preclinical stage; the acquisition’s scientific and financial benefits were uncertain.
- Key risks include clinical efficacy and safety uncertainty, including renal toxicities observed in ELX-02 animal testing at doses above anticipated clinical doses; regulatory and patient-enrollment delays; reliance on third-party research and manufacturing; competition; intellectual-property and funding risks; and integration of Zikani. Management reported disclosure controls effective at June 30, while Zikani’s internal controls were excluded from the evaluation as a newly acquired business.
- No material pending legal proceedings were reported. The filing disclosed contingent repayment and royalty obligations related to Cystic Fibrosis Foundation funding and potential royalty and other obligations under Israeli Innovation Authority grants.
Important facts for investors to verify
- Whether ELX-02 trial data arrived on the stated timeline and support biological activity, safety and further development.
- Actual cash burn and runway against management’s at-least-12-month estimate, including costs of the expanded pipeline and Zikani integration.
- Final Zikani purchase-price allocation and the implications of the acquisition’s large one-time IPR&D charge.
- Debt repayment terms, PPP forgiveness status, and conditions attached to collaboration funding and grants.
- Potential dilution from the large 2021 share issuance and outstanding equity awards; clinical and regulatory risks remain substantial.